Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as an unknown/unknown for intravenous use. It replaces deficient factor IX, restoring the intrinsic pathway of the coagulation cascade and is used to treat hemophilia B and acquired factor IX deficiency in patients with factor IX deficiency.

GNH USA supplies Immunine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Immunine is a recombinant factor IX product that acts on the intrinsic coagulation pathway to manage bleeding disorders.

Hemophilia B: restores clotting ability and reduces bleeding episodes. Acquired factor IX deficiency: provides the missing factor to achieve hemostasis. Peri‑operative management in factor IX‑deficient patients: lowers surgical bleeding risk.

Adverse reactions may occur with any intravenous factor IX product.

Common Side Effects: - Infusion‑related reactions such as chills or fever. - Headache. - Nausea or vomiting. - Arthralgia. - Mild rash at the infusion site. - Transient increase in blood pressure.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of neutralizing antibodies (inhibitors) against factor IX. - Thromboembolic events including deep vein thrombosis. - Severe hypotension. - Renal impairment or failure. - Hemolysis.

Before initiating therapy, clinicians should consider several safety measures.

Dose adjustment: individualize based on measured factor IX activity levels. Monitoring: regularly assess coagulation parameters and clinical response. Allergy assessment: evaluate for hypersensitivity to human plasma‑derived proteins. Inhibitor surveillance: test for development of anti‑factor IX antibodies. Pregnancy and lactation: use only if the potential benefit justifies the potential risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Factor IX replacement can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Antifibrinolytics: may increase thrombosis risk when combined with factor IX. - Concurrent use of other clotting factor concentrates: risk of excessive clot formation. - Activated prothrombin complex concentrates: additive pro‑coagulant effect.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., aminoglycosides) that may affect renal clearance of the product. - Immunosuppressive agents: may influence inhibitor development. - Vaccinations: monitor for altered immune response when administered near factor IX infusions.